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Introduction
Most human cancer vaccine trials target self-antigens that are overexpressed in malignant cells but have limited expression in normal tissues, such as cancer-testis antigens, oncofetal antigens, and melanosomal antigens (1) . Although spontaneous immune responses can develop against certain self/tumor antigens and lead to anti-tumor effects in vitro and in vivo, effectors mediating these immune responses are still regulated by central and peripheral tolerance (2, 3) . Furthermore, cancer cells are known to utilize multiple mechanisms to escape immunosurveillance (4) (5) (6) . As a consequence, achieving consistent polyclonal and high-avidity antibody, CD8
+ and CD4 + T cell responses by cancer vaccination has been challenging.
In animal models, toll-like receptor (TLR) signals were shown to improve the efficacy of cancer vaccines targeting self-antigens (7) . Activation of innate immune cells and production of inflammatory cytokines also play a central role in the induction of self/tumor antigen-specific immune responses (8, 9) . Based on such experimental evidence, several TLR agonists have been developed for use as vaccine immunostimulatory adjuvants in human immunotherapy (10) . However, in clinical trials, the specific effect of TLR ligands has rarely been analyzed primarily due to a lack of comparative control groups. Because the expression pattern of TLR is different between mice and humans, the effect of TLR ligands as adjuvants in humans may differ from experimental animal model predictions (11) .
Therefore, it is critical to understand the in vivo effect of TLR ligands in humans to further improve the composition of cancer vaccines.
TLR3 is an endosomal molecule that recognizes viral double-stranded RNA molecules and plays an important role in anti-viral immunity (12) . Synthetic mimic of double-stranded RNA, polyinosinic-polycytidylic acid (poly-IC) effectively stimulates TLR3 to induce inflammatory responses. In addition, poly-IC stabilized with polylysine and carboxymethylcellulose (poly-ICLC) can enhance the efficacy of self/tumor antigentargeting vaccine in mice (13) . Poly-ICLC has been tested in human clinical trials, and demonstrated safety as well as induction of inflammatory responses (14) . However, its effect as a vaccine adjuvant on the quantity and quality of vaccine-induced immune were not explored in that original study (15) .
We hypothesized that Montanide was important for protecting and slowly releasing the antigen, thereby increasing immunogenicity, while poly-ICLC help prime APC at the injection site and lead to better quality and quantity of effector cells. It has been known that antigen-specific CD4 + T cells are required for the induction and maintenance of cognate antigen-specific antibody and CD8 + T cell responses through direct cell-cell interaction and indirect cytokine production (16, 17 and therefore all patients were analyzed in this study. For patient M02 in Cohort 1, the vaccine was discontinued after week 7 because of disease progression. Therefore, only two time points (pre-vaccine and week 7) were analyzed for M02. Other patients who were analyzed in the present study received all 5 vaccines. In total, the 12 patients selected in the present report represent 60% of patients who completed the original clinical trial. About
1×10
7 cryopreserved PBMCs were used for the analyses. 
Generation of CD4
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To assess differences in the functional avidity of NY-ESO-1-specific vaccineinduced CD4 + T cells, reactivity against titrated amounts of individual 20-mer assay OLP was determined. To facilitate the comparison of apparent avidity for each peptide, an EC 50 value was interpolated from titration curves as the peptide concentration required to induce 50% of the GM-CSF produced from saturating amounts of peptide (10 μM). As shown in 13 cells within T cell lines, cytokine production was normalized against GM-CSF (Fig. 4B) . showed a gradual increase following vaccinations (Fig. 4B) . IL-9-producing CD4 + T cells were also detectable by intracellular cytokine staining (Fig. 6) . The staining demonstrated the presence of both IL-9 single positive cells and IL-9 and IL-4 co-producing cells. In contrast, IFN-γ-producing cells rarely co-produced IL-9. Vaccine-induced differentiation to IL-9-producing cells was completely inhibited by inclusion of poly-ICLC in the adjuvant (Figs. 5 and 6 ). In contrast, no significant difference in cytokine-production was found between the 3 cohorts before vaccination, except for the IFN-γ/IL-4 ratio which was slightly higher in Cohort 1 compared with Cohort 2 (Fig. S2 ). This suggested that differences in cytokine profiles post-vaccination reflected the effect of vaccine adjuvants, and not preexisting variability in precursors. 
and was still able to significantly distinguish characteristics and functions of CD4 + T cells established in vivo by vaccine components. Likely, the differences in CD4 + T cell frequency and quality reflect the effect of adjuvants on APC and their capacity to prime effectors.
Further studies on activation and cytokine-producing profiles for APC subsets in the various cohorts are warranted.
As we reported previously, circulating NY-ESO-1-specific CD4 + T cell precursors capable of recognizing naturally processed NY-ESO-1 protein were detected in many patients before vaccination although at very low frequency (6) . Interestingly, these highavidity precursors became undetectable after vaccination with OLP alone, strongly suggesting that OLP should be administered in a proper carrier system such as Montanide.
Preferential expansion of low-avidity Because the NY-ESO-1-specific IL-9-producing cells were only about 1% of total NY-ESO-1-specific CD4 + T cells (Fig. 6) 
